Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)

Last updated: June 19, 2018
Sponsor: Yonsei University
Overall Status: Active - Recruiting

Phase

4

Condition

Chest Pain

Coronary Artery Disease

Angina

Treatment

N/A

Clinical Study ID

NCT02494895
1-2014-0066
  • Ages 19-79
  • All Genders

Study Summary

To compare the clinical outcomes of dual antiplatelet therapy with aspirin and ticagrelor vs. ticagrelor monotherapy at 3 months after PCI in patients with acute coronary syndrome.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients ≥ 19 years old

  • Patients who received new generation sirolimus-eluting (Osiro®) stent implantation fortreating ACS

  • Patients without significant clinical events such as MI, stent thrombosis orrevascularization until 3 months after PCI

  • Provision of informed consent

Exclusion

Exclusion Criteria:

  • Age > 80 years

  • Increased risk of bleeding, anemia, thrombocytopenia

  • A need for oral anticoagulation therapy

  • Pregnant women or women with potential childbearing

  • Life expectancy < 1 year

  • Patients who treated with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin,nefazodone, ritonavir, or atazanavir)

  • Patients who had history of intracranial hemorrhage

  • Moderate to severe hepatic dysfunction

  • Increased risk of bradycardia-related symptom (Guidance and reference)

Study Design

Total Participants: 3056
Study Start date:
August 01, 2015
Estimated Completion Date:
May 31, 2023

Connect with a study center

  • Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine

    Seoul, 120-752
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.